Biochemical evaluation of low dose of urokinase in acute myocardial infarction. A double-blind study. 1973

J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008259 Macroglobulins Serum globulins with high molecular weight. (Dorland, 28th ed)
D008297 Male Males
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D010958 Plasminogen Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent. Profibrinolysin,Glu-Plasminogen,Glutamic Acid 1-Plasminogen,Glutamyl Plasminogen,1-Plasminogen, Glutamic Acid,Glu Plasminogen,Glutamic Acid 1 Plasminogen,Plasminogen, Glutamyl
D010973 Platelet Adhesiveness The process whereby PLATELETS adhere to something other than platelets, e.g., COLLAGEN; BASEMENT MEMBRANE; MICROFIBRILS; or other "foreign" surfaces. Adhesiveness, Platelet,Adhesivenesses, Platelet,Platelet Adhesivenesses
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
September 1987, Japanese circulation journal,
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
January 1984, Magnesium,
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
May 1989, The American journal of cardiology,
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
October 1974, The Medical journal of Australia,
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
April 1989, Lancet (London, England),
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
September 1990, Journal of the American College of Cardiology,
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
January 1984, Intensive care medicine,
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
December 1985, Zhonghua nei ke za zhi,
J Gormsen, and B Tidstrom, and C Feddersen, and J Ploug
March 1970, The New Zealand medical journal,
Copied contents to your clipboard!